Treatment group (n = 15) | Placebo group (n = 6) | p | |
---|---|---|---|
Agea | 70 (46, 76) | 63 (57, 77) | 0.97 |
Sex-ratio | 6.5 | 2 | 0.54 |
Baseline APACHE IIa | 19 (14, 20) | 15 (9, 19) | 0.22 |
Baseline SOFA Scorea | 8 (5, 10) | 10 (7, 11) | 0.56 |
Source of infection, (n (%)) - Pulmonary - Intra-abdominal - Blood stream - Skin and soft tissue - Endocarditis - Urinary tract | 5 (24%) 5 (24%) 2 (10%) 2 (10%) 1 (5%) 0 | 3 (14%) 0 2 (10%) 0 0 1 (5%) | |
Creatinine, (mmol/L)a | 115 (78, 224) | 155 (80, 553) | 0.54 |
White blood cell, (G/L)a | 15 (10, 20) | 15 (12, 15) | 0.47 |
Lymphocytes, (G/L) a | 0.6 (0.4, 1.0) | 0.6 (0.3, 0.9) | 0.57 |
CD4 T cells, (103cells/µL)a | 0.326 (0.185, 0.673) | 0.637 (0.164, 0.703) | 0.52 |
CD8 T cells, (103cells/µL)a | 0.112 (0.50, 0.216) | 0.134 (0.28, 0.170) | 0.97 |
mHLA-DR, (mAB/cell)a | 4153 (2490, 8010) | 7679 (3938, 13,481) | 0.38 |
Neutrophils, (G/L)a | 12 (9, 18) | 12 (10, 13) | 0.57 |
Monocytes, (G/L)a | 0.5 (0.4, 1.0) | 0.8 (0.7, 0.8) | 0.82 |
Platelets, (G/L)a | 130 (58, 256) | 87 (74, 96) | 0.40 |